Outlook Therapeutics shares are trading lower after the FDA informed the company that an additional adequate and well-controlled clinical trial would be required for the approval of ONS-5010 for the treatment of wet AMD.
Portfolio Pulse from Benzinga Newsdesk
Outlook Therapeutics' shares are trading lower after the FDA informed the company that an additional clinical trial would be required for the approval of ONS-5010 for the treatment of wet AMD.
November 02, 2023 | 4:15 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Outlook Therapeutics' stock price is expected to decrease in the short term due to the FDA's requirement for an additional clinical trial for ONS-5010.
The FDA's requirement for an additional clinical trial for ONS-5010 implies a delay in the drug's approval process. This delay could lead to increased costs and uncertainty, which are likely to negatively impact Outlook Therapeutics' stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100